{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:27:59Z","timestamp":1789504079380,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aesth Plast Surg"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Various botulinumtoxinA formulations are approved for glabellar lines treatment worldwide, including abobotulinumtoxinA (Dysport<jats:sup>\u00ae<\/jats:sup>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Assess abobotulinumtoxinA superiority versus placebo and non-inferiority versus active comparator (onabotulinumtoxinA; Botox<jats:sup>\u00ae<\/jats:sup>), for the treatment of Chinese patients with moderate\/severe glabellar lines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Phase\u00a03, randomized study (NCT02450526) comprising a double-blind (cycle\u00a01) phase and an open-label (cycles 2\u22125) phase. Patients received abobotulinumtoxinA 50\u00a0units or matching placebo (5:1), active comparator (onabotulinumtoxinA 20\u00a0units) or matching placebo (5:1). In cycles 2\u20135, eligible patients were retreated with abobotulinumtoxinA only. Responders had glabellar lines of none\/mild severity. Primary endpoint: responder rates at cycle 1, day 29 at maximum frown with abobotulinumtoxinA versus placebo (for superiority; by investigator\u2019s live assessment [ILA] and subject\u2019s self-assessment [SSA]), and versus active comparator (for non-inferiority; by ILA). Treatment-emergent adverse events were recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 520 patients were randomized. Superiority and non-inferiority, respectively, were demonstrated for abobotulinumtoxinA versus placebo (ILA, SSA; both <jats:italic>p\u2009<\/jats:italic>&lt;\u20090.0001) and abobotulinumtoxinA versus active comparator. AbobotulinumtoxinA efficacy was maintained over open-label cycles; median time to onset of efficacy was 2.0\u00a0days. After 6\u00a0months, 17% of patients treated with abobotulinumtoxinA remained responders. AbobotulinumtoxinA was well-tolerated. Safety results were in line with the known profile of abobotulinumtoxinA; adverse events rate decreased with repeated treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>After a single injection, abobotulinumtoxinA demonstrated superiority versus placebo and non-inferiority versus onabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines in Chinese patients. Multiple injections of abobotulinumtoxinA demonstrated efficacy and safety in the treatment of glabellar lines in Chinese patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Level of Evidence I<\/jats:title>\n                <jats:p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.springer.com\/00266\">www.springer.com\/00266<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00266-022-03164-3","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T21:33:10Z","timestamp":1671485590000},"page":"351-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study"],"prefix":"10.1007","volume":"47","author":[{"given":"Yan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Picaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Prygova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Andriopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"issue":"3","key":"3164_CR1","first-page":"168","volume":"90","author":"R Small","year":"2014","unstructured":"Small R (2014) Botulinum toxin injection for facial wrinkles. Am Fam Physician 90(3):168\u2013175","journal-title":"Am Fam Physician"},{"issue":"3","key":"3164_CR2","doi-asserted-by":"publisher","first-page":"518e","DOI":"10.1097\/01.prs.0000475758.63709.23","volume":"137","author":"H Sundaram","year":"2016","unstructured":"Sundaram H, Signorini M, Liew S, Trindade de Almeida AR, Wu Y, Vieira Braz A, Fagien S, Goodman GJ, Monheit G, Raspaldo H (2016) Global aesthetics consensus: Botulinum Toxin Type A\u2013evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg 137(3):518e\u2013529e","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"3164_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1524-4725.1992.tb03295.x","volume":"18","author":"JD Carruthers","year":"1992","unstructured":"Carruthers JD, Carruthers JA (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18(1):17\u201321","journal-title":"J Dermatol Surg Oncol"},{"issue":"4","key":"3164_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0161-6420(96)30644-1","volume":"103","author":"JA Foster","year":"1996","unstructured":"Foster JA, Barnhorst D, Papay F, Oh PM, Wulc AE (1996) The use of botulinum a toxin to ameliorate facial kinetic frown lines. Ophthalmology 103(4):618\u2013622","journal-title":"Ophthalmology"},{"issue":"4","key":"3164_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0190-9622(96)90682-9","volume":"35","author":"NJ Lowe","year":"1996","unstructured":"Lowe NJ, Maxwell A, Harper H (1996) Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol 35(4):569\u2013572","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3164_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1067\/mjd.2002.121356","volume":"46","author":"JA Carruthers","year":"2002","unstructured":"Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N, Group, B.G.L.I.S (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46(6):840\u2013849","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3164_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/archfaci.2009.5","volume":"11","author":"R Moy","year":"2009","unstructured":"Moy R, Maas C, Monheit G, Huber MB, Reloxin Investigational G (2009) Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 11(2):77\u201383","journal-title":"Arch Facial Plast Surg"},{"issue":"3","key":"3164_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7181\/acfs.2018.01886","volume":"19","author":"S Song","year":"2018","unstructured":"Song S, Lee YH, Hong JP, Oh TS (2018) Safety, efficacy, and onset of a novel botulinum toxin type A (Nabota) for the treatment of glabellar frown lines: a single-arm, prospective, phase 4 clinical study. Arch Craniofac Surg 19(3):168\u2013174","journal-title":"Arch Craniofac Surg"},{"issue":"3","key":"3164_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/PSN.0000000000000236","volume":"38","author":"E Alouf","year":"2018","unstructured":"Alouf E, Murphy T, Alouf G (2018) Botulinum toxin type A: evaluation of onset and satisfaction. Plast Surg Nurs 38(3):105\u2013113","journal-title":"Plast Surg Nurs"},{"key":"3164_CR10","unstructured":"Ipsen Biopharmaceuticals, Inc.: Highlights of prescribing information: Dysport\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125274s107lbl.pdf (2016). Accessed October 21, 2019"},{"key":"3164_CR11","unstructured":"Electronic Medicines Compendium: Azzalure summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/6584\/smpc (2019). Accessed February 17, 2022"},{"issue":"12","key":"3164_CR12","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1111\/j.1524-4725.2009.01235.x","volume":"35","author":"F Brandt","year":"2009","unstructured":"Brandt F, Swanson N, Baumann L, Huber B (2009) Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 35(12):1893\u20131901","journal-title":"Dermatol Surg"},{"issue":"(suppl_1)","key":"3164_CR13","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1093\/asj\/sjx010","volume":"37","author":"JL Cohen","year":"2017","unstructured":"Cohen JL, Scuderi N (2017) Safety and patient satisfaction of AbobotulinumtoxinA for aesthetic use: A systematic review. Aesthet Surg J 37((suppl_1)):S32-44","journal-title":"Aesthet Surg J"},{"issue":"40","key":"3164_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/asj\/sjz003","volume":"1","author":"B Ascher","year":"2020","unstructured":"Ascher B, Rzany B, Kestemont P, Hilton S, Heckmann M, Bodokh I, Noah EM, Boineau D, Kerscher M, Volteau M, Le Berre P, Picaut P (2020) Liquid formulation of abobotulinumtoxinA: a 6-month, phase 3, double-blind, randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthet Surg J 1(40):93\u2013104","journal-title":"Aesthet Surg J"},{"issue":"2","key":"3164_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/asj\/sjw272","volume":"38","author":"B Ascher","year":"2018","unstructured":"Ascher B, Kestemont P, Boineau D, Bodokh I, Stein A, Heckmann M, Dendorfer M, Pavicic T, Volteau M, Tse A, Picaut P, Rzany B (2018) Liquid formulation of AbobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: A randomized, double-blind, placebo- and active comparator-controlled trial. Aesthet Surg J 38(2):183\u2013191","journal-title":"Aesthet Surg J"},{"issue":"(suppl_1)","key":"3164_CR16","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1093\/asj\/sjw282","volume":"37","author":"M Nestor","year":"2017","unstructured":"Nestor M, Ablon G, Pickett A (2017) Key parameters for the use of AbobotulinumtoxinA in aesthetics: Onset and duration. Aesthet Surg J 37((suppl_1)):S20\u2013S31","journal-title":"Aesthet Surg J"},{"issue":"2","key":"3164_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13555-013-0033-y","volume":"3","author":"R Kassir","year":"2013","unstructured":"Kassir R, Kolluru A, Kassir M (2013) Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatol Ther 3(2):179\u2013189","journal-title":"Dermatol Ther"},{"issue":"1","key":"3164_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/DSS.0000000000002013","volume":"46","author":"GD Monheit","year":"2020","unstructured":"Monheit GD, Baumann L, Maas C, Rand R, Down R (2020) Efficacy, safety, and subject satisfaction after AbobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatol Surg 46(1):61\u201369","journal-title":"Dermatol Surg"},{"issue":"12","key":"3164_CR19","first-page":"E56","volume":"13","author":"M Nestor","year":"2020","unstructured":"Nestor M, Cohen JL, Landau M, Hilton S, Nikolis A, Haq S, Viel M, Andriopoulos B, Prygova I, Foster K, Redaelli A, Picaut P (2020) Onset and duration of AbobotulinumtoxinA for aesthetic use in the upper face: A systematic literature review. J Clin Aesthet Dermatol 13(12):E56\u2013E83","journal-title":"J Clin Aesthet Dermatol"},{"issue":"Suppl 4","key":"3164_CR20","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1111\/j.1524-4725.2010.01706.x","volume":"36","author":"G Sattler","year":"2010","unstructured":"Sattler G, Callander MJ, Grablowitz D, Walker T, Bee EK, Rzany B, Flynn TC, Carruthers A (2010) Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 36(Suppl 4):2146\u20132154","journal-title":"Dermatol Surg"},{"issue":"1 Pt 2","key":"3164_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/dsu.12072","volume":"39","author":"CH Won","year":"2013","unstructured":"Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH (2013) Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg 39(1 Pt 2):171\u2013178","journal-title":"Dermatol Surg"},{"issue":"1","key":"3164_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1524-4725.2009.01390.x","volume":"36","author":"Y Wu","year":"2010","unstructured":"Wu Y, Zhao G, Li H, Zheng Z, Zhong S, Yang Z, Feng Z, Yang Q, Zhu X (2010) Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatol Surg 36(1):102\u2013108","journal-title":"Dermatol Surg"},{"issue":"s1","key":"3164_CR23","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1111\/j.1524-4725.2006.32332.x","volume":"33","author":"G Monheit","year":"2007","unstructured":"Monheit G, Carruthers A, Brandt F, Rand R (2007) A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg 33(s1):S51\u2013S59","journal-title":"Dermatol Surg"},{"issue":"3","key":"3164_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/archderm.142.3.320","volume":"142","author":"B Rzany","year":"2006","unstructured":"Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W (2006) Efficacy and safety of 3-and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 142(3):320\u2013326","journal-title":"Arch Dermatol"},{"issue":"11","key":"3164_CR25","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1097\/DSS.0000000000001808","volume":"45","author":"DM-Y Hsieh","year":"2019","unstructured":"Hsieh DM-Y, Zhong S, Tong X, Yuan C, Yang L, Yao AY, Zhou C, Wu Y (2019) A retrospective study of Chinese-specific glabellar contraction patterns. Dermatol Surg 45(11):1406\u20131413","journal-title":"Dermatol Surg"},{"issue":"7","key":"3164_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/asj\/sjv244","volume":"36","author":"BL Chang","year":"2016","unstructured":"Chang BL, Wilson AJ, Taglienti AJ, Chang CS, Folsom N, Percec I (2016) Patient perceived benefit in facial aesthetic procedures: FACE-Q as a tool to study Botulinum Toxin injection outcomes. Aesthet Surg J 36(7):810\u2013820","journal-title":"Aesthet Surg J"},{"issue":"6","key":"3164_CR27","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s00266-018-1200-4","volume":"42","author":"E Gubanova","year":"2018","unstructured":"Gubanova E, Haddad Tabet M, Bergerova Y, Moiseieva O, Chemeris A, Sanches E, Sharova A, Rodriguez Pose L, Raymond R, Prygova I, Carlisle I (2018) Assessment of subject and physician satisfaction after long-term treatment of glabellar lines with AbobotulinumtoxinA (Dysport((R))\/Azzalure((R))): Primary results of the APPEAL noninterventional study. Aesthet Plast Surg 42(6):1672\u20131680","journal-title":"Aesthet Plast Surg"},{"issue":"1","key":"3164_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jocd.12529","volume":"18","author":"E Karbassi","year":"2019","unstructured":"Karbassi E, Nakhaee N, Zamanian M (2019) The efficacy and complications of a new technique of Abobotulinum-toxin A (Dysport) injection in patients with glabellar lines. J Cosmet Dermatol 18(1):55\u201358","journal-title":"J Cosmet Dermatol"},{"key":"3164_CR29","unstructured":"Medicis, I.a.: Joint press release: FDA approves Dysport for therapeutic and aesthetic uses https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/2009\/04\/06182519\/20090430___dysport_usa_10.pdf (2009). Accessed November 26, 2020"},{"key":"3164_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/CCID.S41537","volume":"6","author":"T Rappl","year":"2013","unstructured":"Rappl T, Parvizi D, Friedl H, Wiedner M, May S, Kranzelbinder B, Wurzer P, Hellbom B (2013) Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol 6:211\u2013219","journal-title":"Clin Cosmet Investig Dermatol"}],"updated-by":[{"DOI":"10.1007\/s00266-023-03306-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000}}],"container-title":["Aesthetic Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00266-022-03164-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00266-022-03164-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00266-022-03164-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T14:03:33Z","timestamp":1679580213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00266-022-03164-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3164"],"URL":"https:\/\/doi.org\/10.1007\/s00266-022-03164-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00266-023-03306-1","asserted-by":"object"}]},"ISSN":["0364-216X","1432-5241"],"issn-type":[{"value":"0364-216X","type":"print"},{"value":"1432-5241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00266-023-03306-1","URL":"https:\/\/doi.org\/10.1007\/s00266-023-03306-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yan Wu, Fang Fang, Wei Lai, Chengxin Li, Li Li, Quanzhong Liu, Jianyun Lu, Xiaowen Pang, Jiaming Sun, and Qiuning Sun have no conflicts to declare. Xiaofeng Shi is an employee of Ipsen. Philippe Picaut was an employee of Ipsen during the study and an employee of AlgoTherapeutix at the time of manuscript preparation. Inna Prygova was an employee of Ipsen during the study and an employee of Galderma at the time of manuscript preparation. Bill Andriopoulos was an employee of Galderma at the time of manuscript preparation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}